Ann: Rhythm Biosciences - Investor Webinar Presentation, page-15

Thank you for the link.

I have been buying down here too.

There are clearly a lot of boxes being ticked with this one:

• Large total addressable market (tens of billions) - tick
• Quality management/board (CSL, SHL, CSIRO, J&J, Pfizer) - tick
• Management delivering milestones on time - tick
• Product based on over a decade of research at CSIRO - tick
• Addresses a critical human need (detection of one of our largest killers) - tick
• Near term commercialisation - tick
• Low shares on issue (230m fully diluted) - tick
• Well funded ($10m in the bank) - tick
• Scalable product with manufacturing partnerships in place - tick
• Global market - tick
• IP protection in place across all key markets - tick
• Late stage biotech at a fully diluted market cap under $300m - tick